-
A decrease of IGFBP6 expression can involve a decrease in the expression of N-cadherin and transcription factor Slug.
-
IGFBP-6 could inhibit invasion and migration of colorectal carcinoma cells
-
These findings demonstrated that hMSCCMmediated neuroprotection was attributed to IGF1Rmediated signaling, potentiated via the inhibition of IGF2 by IGFBP6. The results of the present study provide insight into the mechanism by which hMSC administration may promote recovery from nerve injury.
-
IGFBP6 might be an important regulator and prognostic factor for glioma.
-
Results suggest that insulin like growth factor binding protein 6 (IGFBP6) may be an independent prognostic biomarker for nasopharyngeal carcinoma (NPC).
-
We identified a novel SNP variant, Chr12:g.53494591T>C. c.T430C (p.S144P) in the insulin-like growth factor binding protein-6 (IGFBP6) gene. This variant was shared by all affected family members, but not by unaffected members. The c.T430C (p.S144P) variant of IGFBP6 was identified as the likely causal variant associated with increased risk of familial disc degeneration in the studied pedigree.
-
This study thus investigated the relationship between IGFs-related proteins in diabetic patients and the incidence of colorectal carcinoma.
-
We found that IGFBP6 and SATB2 were significantly down-regulated in HIV-infected CEM*174 cells and 3 different cohorts of HIV/AIDS patients while their promoters were predominantly hyper-methylated compared with normal controls.
-
IGFBP6 attenuation in ACTH-secreting pituitary adenomas is associated with tumor growth, through activation of PI3K-AKT-mTOR pathway
-
CCL-18 and IGFBP-6 were identified as new potential serum biomarkers for prostate cancer.
-
When the concentrations of IGFBP-6 or KNG1 were greater than 98.5 pg/ml or 88.5 ng/ml, respectively, they predicted the proliferative vitreoretinopathy prognosis.
-
Our results indicate that IGF2 and IGFBP6 appear to govern various regulatory feedback mechanisms in periodontal ligament cells
-
Data indicate that IGFBP-6 binds to prohibitin-2 on the cell membrane, and knockdown of the latter abrogates IGFBP-6-induced migration.
-
This is the first report to implicate IGFBP-6 as a suppressor of cellular proliferation and IGF-II as an inducer of cellular contractility in this connective tissue disease.
-
Review of the IGF system in physiology and disease with a focus on the regulation and actions of IGFBP-6, and its potential roles in cancer cells.
-
These results suggest that the expression of IGFBP-6 in vascular endothelial cells is up-regulated by hypoxia and IGFBP-6 inhibits angiogenesis in vitro and in vivo
-
IGFBP-6 acts as a inhibitory mediator of thyroid hormone effects in osteoblast differentiation
-
TCDD at low concentrations may have a negative effect on cell apoptosis and down-regulate gene expression of IGFBP-6 in SaOS-2 cells.
-
Hh pathway is aberrant activation in colorectal carcinoma cell line. Its inhibitor may be effectual agent for colorectal cancer chemoprevention. Gli1 maintained cell survival by binding promoter regions and facilitating transcription of IGFBP6 and Bcl-2.
-
When IGFBP-6 gene expression was downregulated, cell proliferation was inhibited and apoptotic cell death was increased.
